Cho Ki-Ho, Kim Young-Suk, Bae Hyung-Sup, Moon Sang-Kwan, Jung Woo Sang, Park Eun-Kyung, Kim Dong-Hyun
College of Oriental Medicine, Kyung Hee University, Seoul, Korea.
Biol Pharm Bull. 2004 Nov;27(11):1810-3. doi: 10.1248/bpb.27.1810.
Chunghyuldan (Daio-Orengedokuto in Japanese) (CHD) has been used as an antihyperlipidemic and antiischemic agent in Korea. To evaluate in vitro the efficacy of Chunghyuldans (CHDs) metabolized with and without human intestinal microflora against brain ischemia, we investigated its anti-inflammatory effect on LPS-induced RAW264.7 cells. Both metabolized CHD (MCHD) and CHD showed antioxidant activities in vitro, and inhibited nitric oxide (NO) and prostaglandin E2 (PGE2) productions in lipopolysaccharide (LPS)-induced RAW264.7 cells. These also inhibited enzyme activities and protein expressions of inducible NO synthase and cyclooxygenase-2 in LPS-induced RAW264.7 cells. MCHD-inhibitory activity against NO and PGE2 productions in LPS-induced RAW264.7 cells was more potent than those of CHD. These results suggest that CHD may show potent anti-inflammatory activity in vivo and can improve brain ischemia.
Chunghyuldan（日语为Daio-Orengedokuto）（CHD）在韩国一直被用作抗高血脂和抗缺血药物。为了在体外评估经人肠道微生物群代谢和未代谢的Chunghyuldans（CHDs）对脑缺血的疗效，我们研究了其对脂多糖（LPS）诱导的RAW264.7细胞的抗炎作用。代谢后的CHD（MCHD）和CHD在体外均表现出抗氧化活性，并抑制LPS诱导的RAW264.7细胞中一氧化氮（NO）和前列腺素E2（PGE2）的产生。它们还抑制LPS诱导的RAW264.7细胞中诱导型NO合酶和环氧化酶-2的酶活性和蛋白表达。MCHD对LPS诱导的RAW264.7细胞中NO和PGE2产生的抑制活性比CHD更强。这些结果表明，CHD在体内可能表现出强大的抗炎活性，并可改善脑缺血。
